Pacira Operating Cash Flow Sales Ratio from 2010 to 2024

PCRX Stock  USD 16.91  0.27  1.62%   
Pacira BioSciences, Operating Cash Flow Sales Ratio yearly trend continues to be fairly stable with very little volatility. Operating Cash Flow Sales Ratio is likely to outpace its year average in 2024. During the period from 2010 to 2024, Pacira BioSciences, Operating Cash Flow Sales Ratio regression line of annual values had r-squared of  0.61 and arithmetic mean of (0.30). View All Fundamentals
 
Operating Cash Flow Sales Ratio  
First Reported
2010-12-31
Previous Quarter
0.2291171
Current Value
0.24
Quarterly Volatility
0.87620845
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pacira BioSciences, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pacira BioSciences,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 79.4 M, Interest Expense of 15.8 M or Selling General Administrative of 63.1 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0014 or PTB Ratio of 1.7. Pacira financial statements analysis is a perfect complement when working with Pacira BioSciences, Valuation or Volatility modules.
  
Check out the analysis of Pacira BioSciences, Correlation against competitors.
For more information on how to buy Pacira Stock please use our How to Invest in Pacira BioSciences, guide.

Latest Pacira BioSciences,'s Operating Cash Flow Sales Ratio Growth Pattern

Below is the plot of the Operating Cash Flow Sales Ratio of Pacira BioSciences, over the last few years. It is Pacira BioSciences,'s Operating Cash Flow Sales Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pacira BioSciences,'s overall financial position and show how it may be relating to other accounts over time.
Operating Cash Flow Sales Ratio10 Years Trend
Slightly volatile
   Operating Cash Flow Sales Ratio   
       Timeline  

Pacira Operating Cash Flow Sales Ratio Regression Statistics

Arithmetic Mean(0.30)
Geometric Mean0.28
Coefficient Of Variation(290.23)
Mean Deviation0.69
Median0.13
Standard Deviation0.88
Sample Variance0.77
Range2.3362
R-Value0.78
Mean Square Error0.32
R-Squared0.61
Significance0.0006
Slope0.15
Total Sum of Squares10.75

Pacira Operating Cash Flow Sales Ratio History

2024 0.24
2022 0.22
2021 0.23
2020 0.18
2019 0.17
2018 0.14
2017 0.062

About Pacira BioSciences, Financial Statements

Pacira BioSciences, investors use historical fundamental indicators, such as Pacira BioSciences,'s Operating Cash Flow Sales Ratio, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Pacira BioSciences,. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Operating Cash Flow Sales Ratio 0.23  0.24 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pacira Stock Analysis

When running Pacira BioSciences,'s price analysis, check to measure Pacira BioSciences,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira BioSciences, is operating at the current time. Most of Pacira BioSciences,'s value examination focuses on studying past and present price action to predict the probability of Pacira BioSciences,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira BioSciences,'s price. Additionally, you may evaluate how the addition of Pacira BioSciences, to your portfolios can decrease your overall portfolio volatility.